ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements
Alivus Life Sciences incorporated a wholly owned pharma subsidiary in Brazil. The company subscribes up to R$500,000 (₹0.90 Cr) for 100% of the new entity.
Alivus Life Sciences Limited successfully conducted its 15th Annual General Meeting on September 8, 2026. All resolutions proposed in the AGM notice were passed with requisite majority.
Alivus reported strong Q1 FY27 results with 6.4% revenue growth, masking a massive 52.6% decline in its legacy GPL business through high-margin non-GPL growth and operational efficiencies.
Alivus Life Sciences delivered strong Q1FY27 performance with revenue at ₹6,404 Mn and EBITDA margins expanding to 36.6%. The company is pivoting towards Non-GPL segments and CDMO growth.
Alivus Life Sciences Ltd reported revenue from operations of ₹640.4 Cr (+6.4% YoY) and net profit of ₹160.1 Cr (+31.8% YoY) for Q1 FY27.
Alivus (ex-Glenmark Life Sciences) reported strong Q4FY26 results with record 33.6% EBITDA margins, driven by non-GPL growth (71% of business) and CDMO recovery.
Alivus (formerly Glenmark Life Sciences) delivered record FY26 EBITDA margins of 33.6%, shifting successfully from GPL dependency to a more profitable non-GPL segment despite a major plant fire and global headwinds.
Alivus reported Q4FY26 revenue of ₹6,891 Mn (6.1% YoY) and PAT of ₹1,627 Mn (14.7% YoY). Strategy shifts from Glenmark-heavy mix to non-GPL (71% of revenue) under Nirma ownership.
Alivus Life Sciences Ltd reported revenue from operations of ₹689.1 Cr (+6.1% YoY) and net profit of ₹162.7 Cr (+14.7% YoY) for Q4 FY26.